Therefore, the suppression of NCOA3 that results in inhibition of estrogen-induced degradation of ESR1, but not degradation induced by fulvestrant or GW5638 [17], could have additional clinical effects for ESR1-positive breast cancer. This evidence concerns the gene ESR1 and breast cancer.